Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of ...

Samsung Bioepis released PYZCHIVA in the United States through its marketing partner, Sandoz. Sandoz is also responsible for sales in Europe, where the product was previously launched. Linda Y.

Samsung Bioepis has now allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous ...

Johnson & Johnson (NYSE: JNJ) has taken legal action against Samsung Bioepis, accusing the South Korean biotech of violating ...

53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy ... a variety of patient needs, Pyzchiva® offers full suite of dosing options and ...

After settling with J&J last fall, Samsung subsequently contracted with Sandoz to market the treatment, which is named Pyzchiva, in the U.S., Canada, and more than two dozen countries in Europe.

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

Samsung Bioepis launched this product, under the brand name Pyzchiva, in the US earlier this week with partner Sandoz. Despite the contract not permitting Samsung to sub-license its rights for an ...